Extended Data Fig. 6: HER3-DXd interaction with the TME.
From: Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
(a–d)Heatmaps showing density of CD4 + (a), CD8 + (b), C8 CD107a + (c) and CD8 GzmB+ cells (d) at baseline and on-treatment in matched samples of responders and non-responders; (e) Heatmaps showing density of CD68+ cells in responders and non-responders.
